Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

The BRAF mutation occurs commonly in papillary thyroid carcinoma (PTC). Previous
investigations of its utility to predict recurrence‐free survival (RFS) and disease‐specific …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Objective To correlate the presence of BRAF V600E mutation with clinicopathological
parameters. Study Design Case-control study. Setting BRAF mutation represents the most …

Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

BACKGROUND: To date, a mutation of the BRAF oncogene is the most common genetic
alteration found in papillary thyroid carcinoma (PTC) and is associated with extrathyroidal …

Importance Papillary thyroid carcinoma (PTC) is the most common endocrine neoplasm. B-
type raf kinase (BRAF) V600E mutation has been proposed as a negative prognostic …

Gene expression profiling shows that, by gene signature, the difference between BRAF-
positive and BRAF-negative PTC is so distinct that BRAF-positive cancer may be regarded …